Lars Wojtecki1, Carlo Colosimo, Romulo Fuentes. 1. Center for Movement Disorders and Neuromodulation, Department of Neurology, Medical Faculty, Heinrich-Heine-University Duesseldorf Duesseldorf, Germany.
Up to date, tens of thousands patients have undergone implantation of deep brain stimulation electrodes – mainly for the treatment of Parkinson's disease, Essential Tremor, and Idiopathic Dystonia. Pizzolato and Mandat (2012) give a short and comprehensive review on the current status of deep brain stimulation for these movement disorders. For this special issue “The development of deep brain stimulation for neurological and psychiatric disorders: clinical, societal, and ethical issues” the reviews of Pizzolato and Mandat (2012) and of Sarem-Aslani and Mullett (2011) give an overview of the state of the art and currently approved indications for this therapy. There is no doubt, that especially in the field of movement disorders, deep brain stimulation is a history of great success in neurological therapy and a most valuable tool for research.However, especially in the light of other articles of this special issue that deal, e.g., with ethical issues, modulation of affect, cognition, and behavior, or possible changes of personality by deep brain stimulation, there remain some major challenges and questions for the future. We will have to conquer these challenges in order to understand and improve the technique – to finally transfer it to a successful therapy for other disorders especially in the neuro-psychiatric domain.These challenges are:To understand the natural history of the diseases and the underlying functional networks and circuits to select the best targets for neuromodulation.Beneficial motor effects of DBS are well described, e.g., there is class one evidence for the usefulness of DBS for Parkinson's disease (Deuschl et al., 2006; Weaver et al., 2009; Williams et al., 2010). However, to determine the real value in improving quality of life we have to gain more insight into the dynamics of the diseases. What is the right time point for implantation? Current data suggest that despite stable long terms effects on motor fluctuations in PD, we might miss the right time window in elderly patients as DBS will not manage to improve axial motor symptoms (Fasano et al., 2010b). On the other hand, prospective studies to examine the benefits of earlier implantation are still on the way. Furthermore, the interactions of disease state, operation, and implantation on cognitive side effects are not fully understood. Although there are many publications that show “on/off” effects on cognitive measurements, some data suggest that the implantation per se – and not the stimulation – might be the main cause of the decline in executive function (Okun et al., 2012). In line with this discussion we have to further study the right stimulation targets for to gain the best outcome. For example, GPI stimulation recognizes a renaissance, as it might be a cognitive safer target for some patients. In order to efficiently access and modulate the neural networks, many findings point into the direction that fiber tracts rather than nuclei might be the right target of choice – not only in PD, but also in thalamic stimulation for essential tremor: some findings suggest that differential stimulation of fiber tracts can be crucial for modulation of distinct symptoms like tremor versus ataxia (Fasano et al., 2010a).To disentangle the mechanisms of action of deep brain stimulation.The discussion about the effects of stimulating different fiber pathways leads to the point were we need a refined understanding of the connections and relationship between the different neural circuits involved in the desired output behavior. When it comes to STN stimulation, stimulation of afferents from cortical areas might be the main mechanism – as studies that used the optogenetic method suggest (Gradinaru et al., 2009). Additionally, volume of tissue activated studies, other functional imaging, microelectrode multi-site recordings, local field potential-, EEG-, and magnetoencephalographic studies, alone or combined, might provide guides to understand the stimulation effects on local and long range neuronal networks.To improve stimulation techniquesOn the basis of a better understanding of the mechanisms underlying DBS, we have to tailor new stimulation techniques. New programming options as interleaving (Wojtecki et al., 2011) and constant current devices (Okun et al., 2012) are on the market now. Furthermore, new electrodes with improved variability of stimulation direction will be helpful. Finally, as a result of disentangling the neuronal network codes (e.g., beta and high frequency oscillations in PD), closed-loop devices (Rouse et al., 2011), that could provide stimulation “on demand,” will hopefully be a major step forward to improve these therapies.To learn from the history of DBS in movement disorders.Especially when discussing modulation of complex behavior in patients with DBS and when we aim to increase the usage and indication of the technique, we have to learn from the lessons of the past. What was the reason for success of DBS in movement disorders? We think that there are four main points: determining the right patients with a distinct diagnosis for therapy, a detailed knowledge of the involved neural circuits, good designed and ethical clinical studies, and interdisciplinary cooperation between specialists (e.g., neurology, neurosurgery). On this basis, the future will be open for more indications and better understanding.
Authors: Günther Deuschl; Carmen Schade-Brittinger; Paul Krack; Jens Volkmann; Helmut Schäfer; Kai Bötzel; Christine Daniels; Angela Deutschländer; Ulrich Dillmann; Wilhelm Eisner; Doreen Gruber; Wolfgang Hamel; Jan Herzog; Rüdiger Hilker; Stephan Klebe; Manja Kloss; Jan Koy; Martin Krause; Andreas Kupsch; Delia Lorenz; Stefan Lorenzl; H Maximilian Mehdorn; Jean Richard Moringlane; Wolfgang Oertel; Marcus O Pinsker; Heinz Reichmann; Alexander Reuss; Gerd-Helge Schneider; Alfons Schnitzler; Ulrich Steude; Volker Sturm; Lars Timmermann; Volker Tronnier; Thomas Trottenberg; Lars Wojtecki; Elisabeth Wolf; Werner Poewe; Jürgen Voges Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: A G Rouse; S R Stanslaski; P Cong; R M Jensen; P Afshar; D Ullestad; R Gupta; G F Molnar; D W Moran; T J Denison Journal: J Neural Eng Date: 2011-05-05 Impact factor: 5.379
Authors: Alfonso Fasano; Luigi M Romito; Antonio Daniele; Carla Piano; Massimiliano Zinno; Anna Rita Bentivoglio; Alberto Albanese Journal: Brain Date: 2010-09 Impact factor: 13.501
Authors: Frances M Weaver; Kenneth Follett; Matthew Stern; Kwan Hur; Crystal Harris; William J Marks; Johannes Rothlind; Oren Sagher; Domenic Reda; Claudia S Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff Bronstein; Gatana Stoner; Jill Heemskerk; Grant D Huang Journal: JAMA Date: 2009-01-07 Impact factor: 56.272